• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Market News Alert: DarioHealth Beats Q4 Expectations, Reports 398% Growth in B2B Recurring Revenue

    3/10/25 9:43:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care
    Get the next $DRIO alert in real time by email

    Digital health leader DarioHealth outperforms forecast with multi-condition platform, 90%+ client retention, 5x ROI for payers, expands Medicare/Medicaid partnerships, accelerates path to profitability with 83 client base, GLP-1 integrations, and surging healthcare adoption

    Market News Alerts Updates: Market News Alerts Reports: DarioHealth Corp. (NASDAQ:DRIO) reported fourth quarter revenue of $7.6 million, beating analyst consensus of $7.39 million. B2B2C recurring revenue surged 398% year-over-year to $5.6 million in Q4, driven by rapid employer and health plan adoption of the company's comprehensive chronic care platform. Gross margins in the B2B2C business exceeded 80% over the past three quarters.

    Full-year 2024 revenue reached $27.0 million, up 32.9% from 2023, while Q4 operating loss decreased by 35% compared to Q1 2024. The company secured 36 new clients in 2024, bringing its total client base to 83 organizations with an impressive client renewal rate above 90%. Dario's solutions have demonstrated significant clinical outcomes, including a 5x ROI for payers and reducing A1C levels for diabetes patients by 2.3 points.

    "Our strategic initiatives yielded remarkable financial improvements throughout 2024 in both our top and bottom line. We are already seeing this positive trajectory continue into 2025," stated CEO Erez Raphael. The company's $34.5 million cash position is expected to fund operations through to operational cash flow breakeven by the end of 2025, with an additional 20% reduction in operating expenses anticipated by Q4 2025.

    Recent strategic expansions, including a Blue Cross Blue Shield agreement and integration with GLP-1 weight management programs, position Dario to continue its rapid growth trajectory in the expanding digital health market.

    During the company's earnings call, CEO Erez Raphael noted: "It's clear that 2024 was transformational year for DarioHealth. We are entering 2025 with strong momentum and solid financial foundation and a clear strategic vision that sets us apart in the healthcare technology space."

    Recent News from Dario:

    • DarioHealth Reports Fourth Quarter and Full year 2024 Financial and Operating Results
    • Dario Expands Behavioral Health Offerings to Include a Provider Network Through Strategic Arrangement with Rula
    • Dario Signs First Healthcare System as Employer Contract, Expanding Market Presence and Recurring Revenue Growth

    * Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by Market News Alerts, a brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This report contains paid promotional content related to DarioHealth and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by DarioHealth prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250310180490/en/

    Market Alerts News Desk

    [email protected]

    Get the next $DRIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRIO

    DatePrice TargetRatingAnalyst
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    5/13/2022$8.75Neutral → Buy
    Alliance Global Partners
    1/26/2022$28.00 → $25.00Buy
    Aegis Capital
    8/19/2021$35.00 → $28.00Buy
    Aegis Capital
    More analyst ratings

    $DRIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025

      Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 7, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 14th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call DetailsDate: Wednesday, May 14th, 2025, 8:30 a.m. Eastern TimeDial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)

      5/7/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives

      $32.5 million funded at close; up to $17.5 million of additional capital available at the Company's option, subject to the achievement of certain revenue thresholds.Capital from the transaction is expected to support execution of strategic plan and fuel continued growth.With this new structure, debt amortization is deferred from the end of 2025 to 2028, allowing the time to generate funds from operations to support the Company's cash flow.NEW YORK, May 1, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced the closing of a debt financing facility for up to $50 million provided by Rand Capital and Callodine

      5/1/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Announces CFO Transition

      NEW YORK, April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief Financial Officer, will retire from his role, effective May 15, 2025. The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company until the end of June, after which he will move to assist the Company in an advisory capacity. "It has been an incredible journey at DarioHealth, and I am proud of what we have accomplished,

      4/21/25 8:30:00 AM ET
      $BNRG
      $DRIO
      $PLUR
      Building Products
      Industrials
      Medical/Dental Instruments
      Health Care

    $DRIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • DarioHealth downgraded by TD Cowen with a new price target

      TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously

      1/29/25 7:36:04 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth upgraded by Alliance Global Partners with a new price target

      Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75

      5/13/22 9:01:42 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Aegis Capital reiterated coverage on DarioHealth with a new price target

      Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously

      1/26/22 10:35:44 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      11/14/24 4:15:15 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      9/12/24 4:37:42 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Nelson Steven Charles bought $12,292 worth of shares (15,000 units at $0.82), increasing direct ownership by 60% to 40,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      9/10/24 6:00:13 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    SEC Filings

    See more

    $DRIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • DarioHealth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - DarioHealth Corp. (0001533998) (Filer)

      5/6/25 7:30:24 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - DarioHealth Corp. (0001533998) (Filer)

      4/28/25 4:05:25 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - DarioHealth Corp. (0001533998) (Filer)

      4/21/25 5:10:40 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DarioHealth Corp.

      SC 13G - DarioHealth Corp. (0001533998) (Subject)

      12/13/24 4:05:12 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DarioHealth Corp.

      SC 13G - DarioHealth Corp. (0001533998) (Subject)

      10/29/24 11:45:28 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

      SC 13G/A - DarioHealth Corp. (0001533998) (Subject)

      2/14/24 4:51:40 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • New insider Leisure Lawrence B. claimed ownership of 258,000 shares (SEC Form 3)

      3 - DarioHealth Corp. (0001533998) (Issuer)

      3/7/25 4:05:19 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Director Kaplan Jon H. was granted 30,000 shares, increasing direct ownership by 37% to 111,574 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      2/25/25 4:02:22 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Stern Adam K

      4 - DarioHealth Corp. (0001533998) (Issuer)

      1/10/25 4:04:16 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Leadership Updates

    Live Leadership Updates

    See more
    • DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors

      Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va

      2/27/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

      Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

      10/28/24 4:44:00 PM ET
      $BMY
      $DRIO
      $NVS
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer

      After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi

      6/5/24 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Financials

    Live finance-specific insights

    See more
    • DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025

      Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 7, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 14th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call DetailsDate: Wednesday, May 14th, 2025, 8:30 a.m. Eastern TimeDial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)

      5/7/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Reports Fourth Quarter and Full year 2024 Financial and Operating Results

      Full-year 2024 revenue increased by 32.9% to $27.0 million from $20.4 million revenue in 2023.Revenue growth driven by B2B2C channel including employers and health plans resulting in recurring revenues which increased by 300% year over year as core business continues to gain traction.Completed $25.6 million equity financing, resulting in a $34.5 million proforma cash balance as of year-end; proforma balance expected to fund operations through operational cash flow breakeven run rate by the end of 2025 with a larger cushion.Revenue growth and efficient post-merger integration resulted in a decrease in operating loss in the quarter ended December 31, 2024, of 35% to $11.7 million on a GAAP bas

      3/10/25 6:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth to Report Fourth Quarter and Full Year 2024 Results on Monday, March 10, 2025

      Company to host conference call and webcast at 8:30am Eastern Time NEW YORK, March 4, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 4th quarter ended December 31st, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Monday, March 10th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call Details Date: Monday, March 10th, 2025, 8:30am ET Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international) Call me™: ht

      3/4/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care